Amgen Inc. (AMGN) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - General

24/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 5

latest quarter score

Earnings Reports

24
Amgen (AMGN) Q2 2026: Six Growth Drivers Power 26% Surge, Securing Long-Term Pipeline Momentum
August 05, 2026
21
Amgen (AMGN) Q2 2025: Volume Surges 13% as 15 Brands Deliver Double-Digit Growth
June 16, 2026
21
Amgen (AMGN) Q4 2025: 13 Products Drive Double-Digit Growth as Rare Disease Tops $5B
June 15, 2026
23
Amgen (AMGN) Q1 2026: Growth Drivers Power 24% Surge, Pipeline and AI Initiatives Set New Paradigm
May 01, 2026
23
Amgen (AMGN) Q3 2025: Volume Growth Hits 14% as 16 Drugs Post Double-Digit Gains
November 05, 2025
17
Amgen (AMGN) Q1 2025: 14% Volume Surge Drives 35% Biosimilars Growth, Pipeline Execution Accelerates
June 30, 2025
Amgen (AMGN) Q3 2024: Pipeline-Driven R&D Spend Rises 35% as Meritide, Rare Disease, and Biosimilars Expand Growth Levers
October 30, 2024
Amgen (AMGN) Q2 2024: Rare Disease Revenue Tops $1.1B, Pipeline Investment Reshapes Margin Outlook
August 06, 2024
Amgen (AMGN) Q1 2024: Rare Disease Sales Top $950M as Meritide Phase III Plans Accelerate
May 02, 2024
Amgen (AMGN) Q4 2023: Horizon Adds $954M, Rare Disease Now 4th Growth Pillar
February 06, 2024
17
Amgen (AMGN) Q3 2023: Rare Disease Platform Adds $945M, Lifting Global Growth Ambitions
October 31, 2023
Amgen (AMGN) Q2 2023: 11% Global Volume Surge Drives Pipeline Acceleration and Horizon Integration Readiness
August 03, 2023
Amgen (AMGN) Q1 2023: 14% Volume Growth Signals Durable Global Demand and Pipeline Leverage
April 27, 2023

Browse all companies